Harvest Fund Management Co. Ltd Invests $111,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)

Harvest Fund Management Co. Ltd acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,761 shares of the biopharmaceutical company’s stock, valued at approximately $111,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. NBC Securities Inc. grew its stake in shares of TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 485 shares during the period. Ashton Thomas Private Wealth LLC acquired a new position in TG Therapeutics in the second quarter valued at approximately $35,000. Blue Trust Inc. grew its position in TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 849 shares during the period. ORG Wealth Partners LLC acquired a new stake in TG Therapeutics during the third quarter worth $53,000. Finally, DekaBank Deutsche Girozentrale purchased a new stake in TG Therapeutics in the first quarter valued at $58,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on TGTX shares. TD Cowen initiated coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective for the company. B. Riley lifted their price target on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. The Goldman Sachs Group boosted their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. increased their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday. Finally, HC Wainwright boosted their target price on TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $40.67.

Insiders Place Their Bets

In related news, Director Sagar Lonial sold 5,000 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the sale, the director now directly owns 100,195 shares of the company’s stock, valued at $3,049,935.80. This represents a 4.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 10.50% of the company’s stock.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX opened at $35.00 on Thursday. The stock’s 50-day moving average is $26.00 and its two-hundred day moving average is $21.95. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The company has a market cap of $5.45 billion, a price-to-earnings ratio of -349.97 and a beta of 2.19. TG Therapeutics, Inc. has a 1-year low of $12.32 and a 1-year high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. During the same quarter in the previous year, the company posted $0.73 EPS. The company’s quarterly revenue was down 49.4% on a year-over-year basis. Analysts forecast that TG Therapeutics, Inc. will post 0.17 EPS for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.